Revvity's 3Q Profit Falls Despite Higher Revenue

Dow Jones

Oct 27, 2025

By Connor Hart

Revvity logged a lower profit in the third quarter as costs rose, despite slightly higher revenue.

The Waltham, Mass., company--which provides health-science solutions, technologies, expertise and services--posted a profit of $46.7 million, or 40 cents a share, for its three months ended Sept. 28, compared with $94.4 million, or 77 cents a share, a year earlier.

Stripping out certain one-time items, earnings were $1.18 a share. Analysts polled by FactSet expected adjusted earnings of $1.14 a share.

Revenue rose 2.2% to $698.9 million, roughly in line with analyst estimates.

Cost of revenue jumped 8.4% to $324.3 million.

Life-sciences revenue ticked up 1% to about $343 million, while diagnostic revenue edged 2% higher, to approximately $356 million.

For the year, Revvity now expects adjusted earnings of $4.90 to $5 a share on revenue of $2.83 billion to $2.88 billion. It had previously guided for adjusted earnings of $4.85 to $4.95 a share on revenue of $2.84 billion to $2.88 billion.

The company's outlook continues to assume organic revenue growth of 2% to 4%.

Shares fell 3.9% to $95.01 in premarket trading.

Revvity's board also on Monday authorized a new $1 billion share-repurchase program.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

October 27, 2025 07:07 ET (11:07 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2578361016"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578361016\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578361016?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-27 19:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578361016","market":"us","top_or_hot":-1,"title":"Revvity's 3Q Profit Falls Despite Higher Revenue","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Revvity logged a lower profit in the third quarter as costs rose, despite slightly higher revenue. \n</p>\n<p>\n  The Waltham, Mass., company--which provides health-science solutions, technologies, expertise and services--posted a profit of $46.7 million, or 40 cents a share, for its three months ended Sept. 28, compared with $94.4 million, or 77 cents a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-time items, earnings were $1.18 a share. Analysts polled by FactSet expected adjusted earnings of $1.14 a share. \n</p>\n<p>\n  Revenue rose 2.2% to $698.9 million, roughly in line with analyst estimates. \n</p>\n<p>\n  Cost of revenue jumped 8.4% to $324.3 million. \n</p>\n<p>\n  Life-sciences revenue ticked up 1% to about $343 million, while diagnostic revenue edged 2% higher, to approximately $356 million. \n</p>\n<p>\n  For the year, Revvity now expects adjusted earnings of $4.90 to $5 a share on revenue of $2.83 billion to $2.88 billion. It had previously guided for adjusted earnings of $4.85 to $4.95 a share on revenue of $2.84 billion to $2.88 billion. \n</p>\n<p>\n  The company's outlook continues to assume organic revenue growth of 2% to 4%. \n</p>\n<p>\n  Shares fell 3.9% to $95.01 in premarket trading. \n</p>\n<p>\n  Revvity's board also on Monday authorized a new $1 billion share-repurchase program. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 27, 2025 07:07 ET (11:07 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revvity's 3Q Profit Falls Despite Higher Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevvity's 3Q Profit Falls Despite Higher Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-27 19:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Revvity logged a lower profit in the third quarter as costs rose, despite slightly higher revenue. \n</p>\n<p>\n  The Waltham, Mass., company--which provides health-science solutions, technologies, expertise and services--posted a profit of $46.7 million, or 40 cents a share, for its three months ended Sept. 28, compared with $94.4 million, or 77 cents a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-time items, earnings were $1.18 a share. Analysts polled by FactSet expected adjusted earnings of $1.14 a share. \n</p>\n<p>\n  Revenue rose 2.2% to $698.9 million, roughly in line with analyst estimates. \n</p>\n<p>\n  Cost of revenue jumped 8.4% to $324.3 million. \n</p>\n<p>\n  Life-sciences revenue ticked up 1% to about $343 million, while diagnostic revenue edged 2% higher, to approximately $356 million. \n</p>\n<p>\n  For the year, Revvity now expects adjusted earnings of $4.90 to $5 a share on revenue of $2.83 billion to $2.88 billion. It had previously guided for adjusted earnings of $4.85 to $4.95 a share on revenue of $2.84 billion to $2.88 billion. \n</p>\n<p>\n  The company's outlook continues to assume organic revenue growth of 2% to 4%. \n</p>\n<p>\n  Shares fell 3.9% to $95.01 in premarket trading. \n</p>\n<p>\n  Revvity's board also on Monday authorized a new $1 billion share-repurchase program. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 27, 2025 07:07 ET (11:07 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVTY","symbol_name":"REVVITY INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2578361016","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578361016","pubTimestamp":1761563220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Revvity logged a lower profit in the third quarter as costs rose, despite slightly higher revenue.The Waltham, Mass., company--which provides health-science solutions, technologies, expertise and services--posted a profit of $46.7 million, or 40 cents a share, for its three months ended Sept. 28, compared with $94.4 million, or 77 cents a share, a year earlier.Stripping out certain one-time items, earnings were $1.18 a share. Analysts polled by FactSet expected adjusted earnings of $1.14 a share.Revenue rose 2.2% to $698.9 million, roughly in line with analyst estimates.Cost of revenue jumped 8.4% to $324.3 million.Life-sciences revenue ticked up 1% to about $343 million, while diagnostic revenue edged 2% higher, to approximately $356 million.For the year, Revvity now expects adjusted earnings of $4.90 to $5 a share on revenue of $2.83 billion to $2.88 billion. It had previously guided for adjusted earnings of $4.85 to $4.95 a share on revenue of $2.84 billion to $2.88 billion.The comp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RVTY":"REVVITY INC","BK4585":"ETF&股票定投概念","BK4121":"生命科学工具和服务","BK4588":"碎股"},"translate_title":"尽管收入增加，Revvity第三季度利润仍下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVTY":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Revvity logged a lower profit in the third quarter as costs rose, despite slightly higher revenue. \n\n\n  The Waltham, Mass., company--which provides health-science solutions, technologies, expertise and services--posted a profit of $46.7 million, or 40 cents a share, for its three months ended Sept. 28, compared with $94.4 million, or 77 cents a share, a year earlier. \n\n\n  Stripping out certain one-time items, earnings were $1.18 a share. Analysts polled by FactSet expected adjusted earnings of $1.14 a share. \n\n\n  Revenue rose 2.2% to $698.9 million, roughly in line with analyst estimates. \n\n\n  Cost of revenue jumped 8.4% to $324.3 million. \n\n\n  Life-sciences revenue ticked up 1% to about $343 million, while diagnostic revenue edged 2% higher, to approximately $356 million. \n\n\n  For the year, Revvity now expects adjusted earnings of $4.90 to $5 a share on revenue of $2.83 billion to $2.88 billion. It had previously guided for adjusted earnings of $4.85 to $4.95 a share on revenue of $2.84 billion to $2.88 billion. \n\n\n  The company's outlook continues to assume organic revenue growth of 2% to 4%. \n\n\n  Shares fell 3.9% to $95.01 in premarket trading. \n\n\n  Revvity's board also on Monday authorized a new $1 billion share-repurchase program. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 27, 2025 07:07 ET (11:07 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}